Dianthus Therapeutics targets severe autoimmune diseases with DNTH103. Read more on DNTH's promise amid competitive ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.

for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients with generalized myasthenia gravis.

Halozyme announces US FDA approval of argenx's Vyvgart Hytrulo prefilled syringe co-formulated with ENHANZE for self-injection for gMG and CIDP: San Diego Monday, April 14, 2025, ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive and adults with chronic inflammatory ...

Amsterdam, the Netherlands Thursday, April 10, 2025, 18:00 Hrs [IST] ...